Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement
08:00am, Wednesday, 24'th Jan 2024
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postpo
Alzheimer's Disease Drug Development: Another Lost Year
03:58am, Tuesday, 05'th Dec 2023
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
12:53pm, Friday, 01'st Dec 2023
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
02:16pm, Friday, 13'th Oct 2023
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any ad
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
11:26am, Thursday, 12'th Oct 2023
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's
3 Biotech Stocks to Buy Before Drug Trials End
12:56pm, Friday, 28'th Jul 2023
Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
New Strong Buy Stocks for April 21st
08:22am, Friday, 21'st Apr 2023
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
New Strong Buy Stocks for April 18th
09:56am, Tuesday, 18'th Apr 2023
EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.
Annovis: Making Sense Of The Interim Analysis
01:13pm, Wednesday, 12'th Apr 2023
Investor confusion surrounding Annovis's interim analysis of its Phase 3 Parkinson's (PD) study highlights the need, in my view, for improved PR processes at Annovis. The company will have ~9 months t
Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock?
01:44pm, Friday, 07'th Apr 2023
Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Annovis And Buntanetap: Asymmetric Risk/Reward Ahead Of Parkinson's Data Readout
12:00pm, Thursday, 30'th Mar 2023
Lead asset buntanetap represents a differentiated, potentially disease-modifying mechanism of action in neurodegenerative diseases. Interim Phase 3 Parkinson's data to be presented today (3/30/23) at
Here's Why Momentum in Annovis Bio, Inc. (ANVS) Should Keep going
09:54am, Thursday, 30'th Mar 2023
Annovis Bio, Inc. (ANVS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
01:00pm, Tuesday, 21'st Mar 2023
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?
11:17am, Friday, 17'th Feb 2023
Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
07:30am, Thursday, 20'th Oct 2022
BERWYN, Pa. , Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that
